Sera Prognostics (NASDAQ:SERA) Earns Buy Rating from Analysts at Craig Hallum

Research analysts at Craig Hallum started coverage on shares of Sera Prognostics (NASDAQ:SERA) in a research report issued to clients and investors on Thursday. The firm set a “buy” rating and a $6.00 price target on the stock. Craig Hallum’s price objective would indicate a potential upside of 192.68% from the company’s previous close.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a research note on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Sera Prognostics Price Performance

NASDAQ SERA opened at $2.05 on Thursday. The business has a 50 day moving average price of $2.01 and a 200 day moving average price of $2.58. The company has a market capitalization of $80.28 million, a P/E ratio of -3.15 and a beta of 0.94. Sera Prognostics has a 1-year low of $1.37 and a 1-year high of $4.09.

Sera Prognostics (NASDAQ:SERA) last posted its earnings results on Wednesday, May 6th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative return on equity of 41.02% and a negative net margin of 56,385.97%. On average, research analysts expect that Sera Prognostics will post -0.58 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Zhenya Lindgardt sold 22,639 shares of Sera Prognostics stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $1.90, for a total transaction of $43,014.10. Following the completion of the transaction, the chief executive officer directly owned 741,287 shares in the company, valued at $1,408,445.30. The trade was a 2.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 51,133 shares of company stock worth $99,174. Insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Sera Prognostics

Several hedge funds have recently bought and sold shares of the stock. Arkadios Wealth Advisors acquired a new position in shares of Sera Prognostics in the first quarter worth $25,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Sera Prognostics during the fourth quarter valued at $31,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Sera Prognostics during the third quarter valued at $38,000. Lido Advisors LLC purchased a new stake in Sera Prognostics during the 3rd quarter worth about $68,000. Finally, Cetera Investment Advisers acquired a new position in Sera Prognostics in the 4th quarter valued at about $74,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.